Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov:79:104943.
doi: 10.1016/j.msard.2023.104943. Epub 2023 Aug 23.

Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study

Harry Jin  1 , Caroline Geiger  2 , Nikki Jessop  3 , Rosetta Pedotti  3 , Catarina Raposo  3 , Louise Whitley  4 , Jeffrey S Brown  5 , Erwan Muros-Le Rouzic  6
Affiliations
Free article

Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study

Harry Jin et al. Mult Scler Relat Disord. 2023 Nov.
Free article

Abstract

Background: The use and potential benefit of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in people living with multiple sclerosis (pwMS) remains poorly studied. The objective of this study is to describe the therapeutic use of anti-SARS-CoV-2 mAbs among pwMS.

Methods: This retrospective cohort study used electronic medical records data from the TriNetX Dataworks USA Network and included adult pwMS, diagnosed with COVID-19, who received anti-SARS-CoV-2 mAbs in the outpatient setting between November 2020 and April 2022. We analyzed COVID-19 severity at anti-SARS-CoV-2 mAb initiation and up to 30 days, stratified by before/after emergence of Omicron variant and by disease-modifying therapy (DMT).

Results: The study included 434 pwMS treated with anti-SARS-CoV-2 mAbs for mild-to-moderate COVID-19, including 270 patients before and 174 after Omicron emergence. Most pwMS were female (80.2%), mean age (SD) was 51.5 (12.5) years. Two-hundred-and-five patients were on DMTs, 51% of whom received anti-CD20s. One patient with moderate COVID-19 was hospitalized whilst receiving glatiramer acetate. No patients required intensive care and there were no deaths. COVID-19 outcomes were comparable following anti-SARS-CoV-2 mAb therapy in patients receiving different DMTs.

Conclusion: Anti-SARS-CoV-2 mAb treatment for pwMS with mild-to-moderate COVID-19 may reduce the risk of COVID-19-related hospitalization and death.

Keywords: Disease-modifying therapy; Electronic health records; Monoclonal antibody; Multiple sclerosis; Observational study; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Harry Jin: was an employee of TriNetX, LLC during completion of the study related to this manuscript. Caroline Geiger: is an employee of Genentech, Inc., and shareholder in F. Hoffmann-La Roche Ltd. Nikki Jessop: is an employee of and shareholder in F. Hoffmann-La Roche Ltd. Rosetta Pedotti: is an employee of and shareholder in F. Hoffmann-La Roche Ltd. Catarina Raposo: is an employee of and shareholder in F. Hoffmann-La Roche Ltd. Louise Whitley: is a Senior Partner at tranScrip Partners Ltd and a consultant to F. Hoffmann-La Roche Ltd. Jeffrey S. Brown: is an employee of TriNetX, LLC. Erwan Muros-Le Rouzic: is an employee of and shareholder in F. Hoffmann-La Roche Ltd.

Similar articles

See all similar articles

Cited by

Supplementary concepts

LinkOut - more resources